Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda’s Alogliptin Falls Prey To U.S. FDA Slowdown

This article was originally published in PharmAsia News

Executive Summary

Takeda's alogliptin for type 2 diabetes has become the latest drug to face an open-ended user fee date delay, due to "internal resource constraints" at U.S. FDA
Advertisement

Related Content

U.S. FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
U.S. FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
Takeda Copes With FDA Delays, Yen Appreciation and Acquisition Drags in 2008
Takeda Copes With FDA Delays, Yen Appreciation and Acquisition Drags in 2008
Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market
Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market

Topics

Advertisement
UsernamePublicRestriction

Register

SC066840

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel